Why the study?
Does combination therapy with an oral anticoagulant and an antiplatelet agent reduce cardiovascular events in patients with peripheral arterial disease compared to antiplatelet therapy alone?
Population
2,161 patients with atherosclerotic peripheral arterial disease
Comparison
Combination therapy with an antiplatelet agent… vs Antiplatelet therapy alone
Design
RCT, Randomly assigned
Follow-up
mean 35 months
Loading...
Role of anticoagulants in PAD remains uncertain; leaves open net benefit of combination therapy and requires randomized confirmation.
Does combination therapy with an oral anticoagulant and an antiplatelet agent reduce cardiovascular events in patients with peripheral arterial disease compared to antiplatelet therapy alone?
In patients with peripheral arterial disease, adding an oral anticoagulant to antiplatelet therapy does not reduce major cardiovascular events but significantly increases the risk of life-threatening bleeding.
A 2007 study studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: